Powder/Bulk Solids is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Utility Menu

Powder/Bulk Solids

The Source for Dry Processing and Bulk Handling Technology

Catalent Buys Bristol-Myers Squibb Production Facility

January 14, 2020

Pharmaceutical and health care products firm Catalent recently wrapped up its acquisition of an biologics, sterile, and oral solid dose manufacturing and packaging plant in Anagni, Italy from biopharmaceutical company Bristol-Myers Squibb, the companies announced on January 7 in separate press releases. 

“The Anagni facility supplements our European commercial supply capabilities and will integrate well with our existing global early development and clinical supply sites to smooth the transition from development to commercial supply,” Alessandro Maselli, president and chief operating officer of Catalent, said in a statement. “Anagni provides our European customers with great biologics and oral dose capabilities that can help us reduce time-to-market, simplify tech transfers, and minimize program risk.”

The 305,000-sq-ft facility includes capabilities for aseptic liquid and powder filling for biologics and sterile products in various sizes of vials. The site also has primary and secondary packaging solutions for launching oral solids, sterile, and biologics products. 

Under the terms of the deal, Catalent will continue to manufacture Bristol-Myers Squibb products that are currently produced at Anagni. Bristol-Myers Squibb manufactures cardiovascular, anticancer, metabolic, and anti-inflammatory drugs and packages the products at the facility.

“The divestiture is part of Bristol-Myers Squibb’s strategy to simplify and to realign its business portfolio to address changes in its business and the future requirements of its evolving pipeline,” the company said in its release

In April 2019, Catalent announced plans to invest $40 million to upgrade its solid dose formulation and production capabilities at its production plant in Winchester, KY. The Somerset, NJ-based company said it will acquire new equipment that will enable the facility to expand its capacity for controlled-release tablets and capsules, including a laser drill used in osmotic drug delivery, stick pack dosage manufacturing solutions, roller compaction equipment, and fluid beds. Catalent also intends to install a spray dryer that will be used to scale up products from their development stage and a bottling line. 

For more news headlines, articles, and equipment reviews, visit our Equipment Zones

More Pharmaceutical Industry articles:

Smart Pharma Production, Inspection, and Packaging Equipment

Velesco Pharma to Expand Clinical Manufacturing Capacity

Bayer Names New Head of Pharma Business Development